Literature DB >> 27469363

Molecular Imaging of Immunotherapy Targets in Cancer.

Emily B Ehlerding1, Christopher G England1, Douglas G McNeel2, Weibo Cai3.   

Abstract

Immunotherapy has emerged as a promising alternative in the arsenal against cancer by harnessing the power of the immune system to specifically target malignant tissues. As the field of immunotherapy continues to expand, researchers will require newer methods for studying the interactions between the immune system, tumor cells, and immunotherapy agents. Recently, several noninvasive imaging strategies have been used to map the biodistribution of immune checkpoint molecules, monitor the efficacy and potential toxicities of the treatments, and identify patients who are likely to benefit from immunotherapies. In this review, we outline the current applications of noninvasive techniques for the preclinical imaging of immunotherapy targets and suggest future pathways for molecular imaging to contribute to this developing field.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  CTLA-4; PD-1; PD-L1; immune checkpoints; immunotherapy; positron emission tomography (PET)

Mesh:

Year:  2016        PMID: 27469363      PMCID: PMC5050107          DOI: 10.2967/jnumed.116.177493

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.

Authors:  Sandra Heskamp; Willemijn Hobo; Janneke D M Molkenboer-Kuenen; Daniel Olive; Wim J G Oyen; Harry Dolstra; Otto C Boerman
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 2.  Ipilimumab in the treatment of advanced melanoma - a clinical update.

Authors:  Dae Won Kim; Van Anh Trinh; Wen-Jen Hwu
Journal:  Expert Opin Biol Ther       Date:  2014-09-24       Impact factor: 4.388

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Authors:  Richard Tavaré; Helena Escuin-Ordinas; Stephen Mok; Melissa N McCracken; Kirstin A Zettlitz; Felix B Salazar; Owen N Witte; Antoni Ribas; Anna M Wu
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

Review 6.  Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.

Authors:  Igor N Ivashko; Jill M Kolesar
Journal:  Am J Health Syst Pharm       Date:  2016-02-15       Impact factor: 2.637

7.  Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.

Authors:  Anders Josefsson; Jessie R Nedrow; Sunju Park; Sangeeta Ray Banerjee; Andrew Rittenbach; Fabien Jammes; Benjamin Tsui; George Sgouros
Journal:  Cancer Res       Date:  2015-11-10       Impact factor: 12.701

8.  Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer.

Authors:  Adam Antczak; Dorota Pastuszak-Lewandoska; Paweł Górski; Daria Domańska; Monika Migdalska-Sęk; Karolina Czarnecka; Ewa Nawrot; Jacek Kordiak; Ewa Brzeziańska
Journal:  Biomed Res Int       Date:  2013-07-09       Impact factor: 3.411

9.  64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.

Authors:  Kei Higashikawa; Katsuharu Yagi; Keiko Watanabe; Shinichiro Kamino; Masashi Ueda; Makoto Hiromura; Shuichi Enomoto
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 10.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

View more
  36 in total

1.  Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.

Authors:  Jelena Levi; Tina Lam; Samuel R Goth; Shahriar Yaghoubi; Jennifer Bates; Gang Ren; Salma Jivan; Tony L Huynh; Joseph E Blecha; Roli Khattri; Karl F Schmidt; Dominique Jennings; Henry VanBrocklin
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 3.  Noninvasive PET Imaging of T cells.

Authors:  Weijun Wei; Dawei Jiang; Emily B Ehlerding; Quanyong Luo; Weibo Cai
Journal:  Trends Cancer       Date:  2018-04-17

4.  Predicting PD-1/PD-L1 status in bladder cancer with 18F-FDG PET?

Authors:  Emily B Ehlerding; Xiaoli Lan; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-11       Impact factor: 9.236

Review 5.  The Immunoimaging Toolbox.

Authors:  Aaron T Mayer; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2018-05-24       Impact factor: 10.057

6.  The new era of cancer immunotherapy: what can molecular imaging do to help?

Authors:  Laura Evangelista; Marion de Jong; Silvana Del Vecchio; Weibo Cai
Journal:  Clin Transl Imaging       Date:  2017-07-21

Review 7.  Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.

Authors:  W Joost Lesterhuis; Anthony Bosco; Michael J Millward; Michael Small; Anna K Nowak; Richard A Lake
Journal:  Nat Rev Drug Discov       Date:  2017-01-06       Impact factor: 84.694

8.  Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab.

Authors:  Emily B Ehlerding; Hye Jin Lee; Todd E Barnhart; Dawei Jiang; Lei Kang; Douglas G McNeel; Jonathan W Engle; Weibo Cai
Journal:  Bioconjug Chem       Date:  2019-04-19       Impact factor: 4.774

Review 9.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

Review 10.  Imaging of Cancer Immunotherapy: Current Approaches and Future Directions.

Authors:  Mizuki Nishino; Hiroto Hatabu; F Stephen Hodi
Journal:  Radiology       Date:  2018-11-20       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.